This product is suitable for moderate and severe infections caused by β-lactamase-producing bacteria that are resistant to piperacillin but sensitive to piperacillin and tazobactam:
1. Appendicitis (with perforation or abscess) due to piperacillin-resistant, beta-lactamase-producing Escherichia coli and Bacteroides species (Bacteroides fragilis, Bacteroides ovale, Bacteroides polymorpha, or Bacteroides vulgaris) and peritonitis.
2. Uncomplicated and complex skin and soft tissue infections, including cellulitis, skin abscesses, and ischemic or diabetic foot infections, caused by piperacillin-resistant, beta-lactamase-producing Staphylococcus aureus.
Reyoung pharmaceutical CO.,LTD was established in 1966, is a modern comprehensive pharmaceutical company in China. Reyoung is given the title of National Trustworthy Company for Contract and Credit, Grade AAA Credit Company and Credit Company of Shandong Medical Industry. In the past 50 years, Reyoung inherits the mission Reyoung Pharma, Benefit the public, never stop exploration and innovation, forging ahead with determination and realizing the sustainable healthy development.
Now Reyoung consists of 3 factory sites, covering an area of 1 million square meter , possessing more than 30 workshops(9 categories, and 400 strengths) , focusing on developing , manufacturing and selling Powder for injection(Lyophilized powder for injection is included), Small volume injection, Traditional Chinese Medicine, Tablets, Capsules, Granules, Suppository, Mixtures and APIs.
All the workshops have been passed the Chinese GMP. Reyoung also passed the foreign audit including PIC/S GMP, Ethiopia, Uganda, Kenya, TFDA, NAFDAC, Ghana, Cote d'loire, Pakistan ect. Reyoung focus on the domestic and foreign market. Reyoung processes professional marketing teams, more than 160 representative offices spreading all over China. We commenced international business from 1997, and Reyoung products sell to more than 70 countries and NGOs all over the world.
Audited Supplier 
){kind=link}